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Significance 18 
Bunyamwera virus (BUNV) is the prototype of the Orthobunyavirus genus and Bunyaviridae 19 
family that contains important human and animal pathogens. The cleavage mechanism of 20 
orthobunyavirus glycoprotein precursor (GPC) and the host proteases involved have not 21 
been clarified. Here we found that NSm and Gc contain their own internal signal peptides 22 
(SPs) which mediate the GPC cleavage by host signal peptidase (SPase) and signal peptide 23 
peptidase (SPP). Furthermore, the NSm domain-I (SPNSm) plays an important post-cleavage 24 
role in cell fusion. Our data clarified the implication of host proteases in the processing of 25 
the orthobunyavirus GPC. This identifies SPP as a potential intervention target and the 26 
knowledge we gained will benefit the preventive strategies against other orthobunyavirus 27 
infections. 28 
  29 
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Abstract 30 
The M genome segment of Bunyamwera virus (BUNV), the prototype of both the 31 
Bunyaviridae family and the Orthobunyavirus genus, encodes the glycoprotein precursor 32 
(GPC) that is proteolytically cleaved to yield two structural glycoproteins, Gn and Gc, and a 33 
nonstructural protein NSm. The cleavage mechanism of orthobunyavirus GPCs and the host 34 
proteases involved have not been clarified. In this study, we investigated the processing of 35 
BUNV GPC and found that both NSm and Gc proteins were cleaved at their own internal 36 
signal peptides (SPs), in which NSm domain-I functions as SPNSm and NSm domain-V as SPGc. 37 
Moreover, the domain-I was further processed by a host intramembrane-cleaving protease, 38 
signal peptide peptidase (SPP) and is required for cell fusion activities. Meanwhile, the NSm 39 
domain-V (SPGc) remains integral to NSm, rendering the NSm topology as a two-membrane-40 
spanning integral membrane protein. We defined the cleavage sites and boundaries 41 
between the processed proteins: Gn, from residue 17 to 312 or nearby residues; NSm, 332 42 
to 477; and Gc, 478 to 1432. Our data clarified the mechanism of the precursor cleavage 43 
process, which is important for our understanding of viral glycoprotein biogenesis in the 44 
genus Orthobunyavirus and thus presents a useful target for intervention strategies. 45 
 46 
 47 
\body 48 
The family Bunyaviridae contains more than 350 named viruses that are classified into the 49 
five genera Orthobunyavirus, Hantavirus, Nairovirus, Phlebovirus, and Tospovirus, making it 50 
one of the largest families of RNA viruses. Several members of the family are serious human 51 
pathogens, such as La Crosse virus (LACV) and Oropouche virus (OROV) (Orthobunyavirus), 52 
Hantaan (HTNV) and Sin Nombre viruses (Hantavirus), Rift Valley fever virus (RVFV) 53 
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Phlebovirus) and severe fever with thrombocytopenia syndrome Virus (SFTSV) (Phlebovirus), 54 
Crimean-Congo hemorrhagic fever virus (CCHFV, Nairovirus) (1, 2). The characteristic 55 
features of bunyaviruses include a tripartite single-stranded RNA genome of negative- or 56 
ambi-sense polarity, cytoplasmic site of viral replication, and assembly and budding at 57 
membranes of the Golgi complex (1-3). Bunyamwera virus (BUNV), the prototype of both 58 
the family and the Orthobunyavirus genus, remains an important research model for many 59 
pathogens within this family.  60 
The medium (M) genomic RNA segment of orthobunyaviruses encodes the glycoprotein 61 
precursor (GPC; in order Gn-NSm-Gc) that is cotranslationally cleaved to yield the mature 62 
viral glycoproteins Gn and Gc, and a nonstructural protein NSm. Gn and Gc form viral spikes 63 
that play a crucial role in virus entry (1, 2). Both Gn and Gc are type I integral 64 
transmembrane proteins and form a heterodimer in the endoplasmic reticulum (ER) prior to 65 
trafficking to, and retention in, the Golgi compartment where virus assembly occurs (2, 4, 66 
5). Bunyavirus glycoproteins are fusogenic and the fusion peptide is located on Gc, a class II 67 
fusion protein (6), but cell fusion requires the co-expression of both Gn and Gc 68 
glycoproteins (7). NSm, an integral membrane protein, comprises three hydrophobic 69 
domains (I, III and V) and two non-hydrophobic domains (II and IV) (Fig. S1A) and its N-70 
terminal domain (I) is required for BUNV replication (8). 71 
Cleavage of BUNV GPC is mediated by host proteases, but the details of which 72 
proteases are involved and the precise cleavage sites have not been clarified. Experimental 73 
data on GPC processing has only been reported for snowshoe hare orthobunyavirus (SSHV); 74 
the carboxyl terminus of SSHV Gn was determined by C-terminal amino acid sequencing to 75 
be an arginine (R) residue at position 299 (9) (Fig. S1B). Based on alignments of several 76 
orthobunyavirus GPC sequences, it was suggested that Gn-NSm cleavage occurs at a similar 77 
position to that defined for SSHV (10). This arginine (302R for BUNV) appears conserved in 78 
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GPCs of all orthobunyaviruses analyzed to date, and for most of the viruses lies in the 79 
sequence R-V/A-A-R (Fig. S1C), which has been believed as the site of Gn-NSm cleavage by 80 
furin-like proteases (11).  81 
In eukaryotes, most secreted and membrane proteins contain cleavable N-terminal 82 
signal peptides (SPs), which are recognized by the signal recognition particles (SRP) when 83 
nascent polypeptide chains emerged from the ribosome at ER and translocate it into the ER 84 
lumen where they are usually cleaved by cellular signal peptidases (SPase) (12). The 85 
imbedded peptide remnant is usually subsequently released for degradation by the cellular 86 
signal peptide peptidase (SPP) or SPP-like proteases, which belong to the family of 87 
intramembrane-cleaving aspartyl proteases (I-CliPs) (13-16). SPP is an ER-resident I-CliPs 88 
(17) and is implicated in other important biological functions, such as in generating C-89 
terminal peptides for MHC class I presentation (18) and human lymphocyte antigen E (HLA-90 
E) epitopes (19). SPP activities also involve in the intra-membrane cleavage of the core 91 
proteins of hepatitis C virus (HCV), GB virus B and classical swine fever virus (CSFV) (family 92 
Flaviviridae) (20, 21).  93 
To investigate the cleavage events of orthobunyavirus GPC, we used several 94 
approaches including mutagenesis, virus assays, RNA interference, mass spectrometry and 95 
biological assays. We aimed to determine the cleavage sites between the boundaries of the 96 
mature proteins, e.g. Gn and NSm, and NSm and Gc. Our data revealed the implementation 97 
of the cellular SPase and SPP in the cleavage of BUNV GPC and clarified the mechanism of 98 
orthobunyaviruses GPC cleavage. 99 
 100 
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Results 101 
Gn-NSm Cleavage Does Not Occur at the RVAR Motif by Furin-like Proteases. We first 102 
investigated whether the Gn-NSm cleavage takes place between residues 302R and 303R at 103 
the RVAR motif (Fig. S1). Five mutations were generated at this site in the M expression 104 
plasmid pTM1BUNM, including a deletion mutation (∆RVAR) and four substitution 105 
mutations (MMKR, AAAA, RSLK and RRKR) (Fig. 1A). These plasmids were transfected into 106 
BSR-T7/5 cells and the radiolabeled viral proteins were immunoprecipitated with anti-BUN 107 
serum followed by SDS-PAGE fractionation. Interestingly, like the wild-type (wt) BUNM 108 
control, all mutated GPCs were cleaved into Gn, NSm and Gc (Fig. 1B), suggesting this 109 
location is not a cleavage site by furin-like proteases. Furthermore, the furin inhibitor I (dec-110 
RVKR-cmk, Calbiochem) had no effect on the BUNV GPC cleavage (Fig. S2A) and yields of 111 
virus produced in the presence of the drug over 30 hrs (Fig. S2B).  112 
There exist eight residues between residues 302R and 311S at Gn-NSm junction (Fig. S1 113 
and Fig. 1C). To investigate whether these residues harbor the Gn-NSm cleavage site, we 114 
constructed six mutants that contain internal progressive deletions between residues 298L 115 
and 311S (Fig. 1C). As shown in Fig 1D, all mutated precursors were properly cleaved. 116 
Moreover, the deletions resulted in the increased migration of Gn bands on the gel, with a 117 
relative shift corresponding to the number of amino acids removed (lanes 3 to 8), 118 
suggesting that these residues still belong to the Gn cytoplasmic tail (Gn CT) and the Gn-119 
NSm cleavage must occur at or within NSm domain-I. 120 
NSm Domain-I Functions as an Internal Signal Peptide. After excluding the Gn-NSm 121 
cleavage at motif RVAR302, we speculated that NSm domain-I, a type II transmembrane 122 
domain (TMD), could function as an internal SP for NSm (SPNSm). Using SignalP 4.1 server 123 
(www.cbs.dtu.dk/services/SignalP/) (22) the domain was predicted as a cleavable internal 124 
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SP that cleaves between residues 331G and 332T (Fig. S3A and Fig.2A). It has been reported 125 
that the residues at the -3 and -1 positions relative to the SPase cleavage site are most 126 
critical for cleavage by cellular SPase complex (23). Therefore, we generated a series of 127 
mutant GPCs, including six substitution mutations at the -3 and -1 positions and one 128 
substitution mutation in the core region of the domain (SPm) (Fig. 2A). When the residues 129 
at either -3 (329I) or -1 (331G), or at both positions, were changed to the charged arginine 130 
(R), the NSm protein was not detected (Fig. 2B, lanes 2, 4 and 6). However, substitution with 131 
alanine at these positions and substitution mutation within the domain (SPm) did not affect 132 
Gn-NSm cleavage (lanes 3, 5, 7 and 8) in that NSm was clearly seen. Furthermore, we 133 
purified NSm protein from the cells infected with recombinant virus, rBUNNSmV5, in which 134 
the V5-epitope was inserted in the NSm cytoplasmic domain (Fig. S3B), for mass 135 
spectrometric (MS) analysis and confirmed that the residue 332T is the first N-terminal 136 
residues of NSm (Fig. S3C and S3D). 137 
The effects of the mutations on glycoprotein function were also assessed with regard to 138 
the Golgi trafficking and cell fusion activities. Consistent with the above observation, the 139 
arginine substitutions at -3 and -1 position totally abolished Golgi targeting (Fig. 2C, panels 140 
c, e, and g) and cell fusion (panels d, f and h), whereas alanine substitution had no effect on 141 
either Golgi colocalization (panels l, o and r) or cell fusion (panels m, p and s). When these 142 
mutations were tested for virus rescue, we were able to generate viruses from M segment 143 
mutants containing alanine substitution mutations (rAEG, rIEA and rAEA), but not from 144 
arginine substitution mutants. The rescued viruses showed similar plaque phenotypes to 145 
the wt control (panels n, q and t). Taken together, our data confirmed that the NSm 146 
domain-I functions as an internal SPNSm. 147 
Mapping the C-termini of Gn Protein. After SPase cleavage of SPNSm at residue 332T, 148 
the SP is still attached to the upstream Gn CT (preGn). To define the Gn end, we constructed 149 
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a series of individual Gn mutants that terminate between residues 298 to 332 (Fig. 3A). 150 
Consistent with the earlier results from internal deletions, the deletions from residues 312 151 
to 298 resulted in the linear reduction in the molecular weight of Gn proteins (Fig. 3B, lanes 152 
4 to 7) and Gn312 is comparable in size to wt Gn (comparing lanes 3 and 7), indicating that 153 
Gn likely ends at residue 312 or nearby residues. However, deletions in SPNSm did not cause 154 
a linear reduction in Gn molecular weights (lanes 8 to 10). It is noticeable that Gn317, which 155 
contains only five remnant hydrophobic residues at the C-terminus, produced a smaller 156 
band (about 25 kDa), which we believed to be a degradation product (lane 8). We also 157 
compared the size of the intracellular and virion Gn proteins and found no difference (Fig. 158 
3C), confirming the intracellular and virion Gn proteins end at same position. 159 
To confirm the subsequent processing of SPNSm upon SPase cleavage, we constructed a 160 
mutated Gn (Gn308V5) with domain-I replaced with non-hydrophobic V5 epitope and a 161 
further 6 residues from the Gc CT (QEIKQK) (Fig. 3A). It is worth mentioning that the 162 
unprocessed Gn332 (preGn) would be similar in size to Gn308V5 (35.33 v 35.12 kDa). As 163 
anticipated, Gn308V5 runs at a higher molecular weight than wt Gn and the processed 164 
Gn332 (Fig. 3D), indicating that SPNSm was further processed from preGn. The preGn was 165 
visible by Western blot (WB) analysis of V5-tagged Gn proteins (Gn-27V5 and Gn-86V5) as a 166 
faint band above the predominant processed Gn protein (Fig. 3E). Cell fusion assays with Gn 167 
mutants (in co-expression with Gc) indicated that the extensive syncytia were formed only 168 
from cells coexpressing Gc and Gn332 (PreGn), and any deletions in SPNSm diminished the 169 
cell fusion (Fig 3F), suggesting that the liberated SPNSm is required in cell fusion. 170 
MS analysis of virion Gn protein identified 17S as the first residue of the processed Gn 171 
protein (Fig. S4B), but unable to confirm the Gn end, with the furthest C-terminal residue 172 
was mapped to 303R (Fig. S4C and SI Table ), similar to the previously determined SSHV Gn 173 
end (9). It is probably due to the fact that the newly identified Gn C-terminal residues (303 174 
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to 312) is rich in positively charged arginine and lysine residues being targets by trypsin-like 175 
proteases (24). The terminal residues identified by MS are summarized in Table S1. 176 
NSm domain-V functions as an internal noncleavable SPGc. Our previous study 177 
suggested that NSm domain-V functions as a SPGc (8). Indeed, the deletion of the domain 178 
abolished Gc processing as no Gc protein was detected from the mutated BUNV GPCs that 179 
contain whole or partial internal deletion in the domain (Fig. 4A, lanes 4 to 6). To study 180 
whether the domain undergoes any further processing as SPNSm, we compared the size of C-181 
terminal truncated NSm proteins (based on pTmBUNGn-NSmV5) (Fig. 4B). The deletions 182 
resulted in the increased migration shift of NSm bands (Fig. 4C, lanes 4 to 8). NSm476 that 183 
contains the intact domain-V was identical in size with the parental NSmV5 (comparing 184 
lanes 9 and 10), indicating that domain-V is not further cleaved. Furthermore, no size 185 
change was noticeable when the domain-V was swapped by either non-hydrophobic 186 
residues from EGFP (residues 1 to 20) or hydrophobic signal peptide of Hantaan virus 187 
(HTNV, strain 76-118) Gn protein (SPHGn, residues 1 to 19) (Fig. 4D), whereas NSm456 that 188 
lacks the domain-V was obviously smaller (Fig. 4D, lane 6), providing corroborating evidence 189 
that SPGc remains integral to the mature NSm. This renders the topology of mature NSm as a 190 
two-membrane-spanning protein (residues 332 to 477) that consists of the ectodomain (II), 191 
TMD (III), endoplasmic loop (IV) and C-terminal type-II TMD (V) (Fig.4E).  192 
Requirement of SPNSm for Cell Fusion and Virus Replication. To further investigate the role 193 
of SPNSm in virus replication, we made four mutant GPC constructs (Fig. 5A), and compared 194 
the impact of mutations in promoting cell fusion and virus viability. All four mutated GPCs 195 
were cleaved into Gn and Gc, and also NSm from the BUNM-SPmNSm and -SPNSm/HTNtm (Fig. 196 
5B). A cell fusion assay revealed that only the GPC-∆NSm_I, which contained deletion of 197 
whole mature NSm (residues 332 to 477) but retained SPNSm for Gc translocation, produced 198 
extensive syncytial formation (Fig. 5C). For other three GPC mutants, the domain-V, SPmNSm, 199 
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and SPNSm/HTNtm functioned properly as SPGc for GPC processing, but these mutated GPCs 200 
failed to cause cell fusion. Consistently, from GPC-∆NSm_I we rescued a recombinant virus 201 
(rBUN∆NSm) that did not express NSm protein (Fig. 5D, lane 4). The rBUN∆NSm was 202 
attenuated, evidenced by smaller plaque phenotype (Fig. 5E) and reduced virus yield at late 203 
infection (Fig. 5F). As BUNV NSm is one of key factors in the Golgi associated “virus factory”, 204 
the depletion of the protein likely affects the virus assembly (8, 25, 26). The same strategy 205 
was used to create a viable recombinant OROV lacking NSm (27). 206 
To characterize further SPNSm, we assessed the effect of the deletion mutations in the 207 
domain on GPC processing and cell fusion. As we mentioned early, deletions in SPNSm did not 208 
lead to a linear reduction in the molecular weight of Gn proteins (Fig. 5G). The Gn bands 209 
from Gn324 to Gn332 are comparable in size with wt Gn (lanes 6 to 11), but further deletion 210 
towards Gn312 (in the case of Gn317 and Gn322) would interrupt the proper processing of 211 
Gn protein (lanes 4 and 5), suggesting that the processing requires the stable SP TMD 212 
structure. When these mutants were tested in cell fusion, we noticed that even removal of 213 
two residues from SPNSm (Gn330) had a significant impact on syncytia formation and that 214 
further deletions diminished the extent of cell fusion (Fig. 5H). The data together indicated 215 
that in addition to the role as SP, the liberated SPNSm has post-cleavage function. 216 
Involvement of SPP in the Processing of BUNV GPC. As SPP is the ER-resident I-Clips, we 217 
suspect that SPP is probably involved in the further processing of SPNSm. To address the 218 
issue, we generated three lentiviruses that express small hairpin RNAs (shRNAs): two 219 
specific to human SPP mRNA and one to EGFP (shGFP) as negative control. Both shSPP1 and 220 
shSPP2 were able to inhibit the SPP expression in the transduced A549 cells (shSPP2 showed 221 
a better silencing effect) (Fig. 6A). We then examined the impact of SPP knockdown on 222 
BUNV replication following low multiplicity infection of A549V cells (MOI of 0.01 pfu/cell). 223 
WB analysis showed that the detection of BUNV N was delayed by 24 hrs in shSPP-silenced 224 
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cells compared with shGFP control (Fig. 6B) and the virus titre in SPP-knockdown cells was 225 
over 10-fold lower than controls across the infection period (Fig, 6C). This indicates the 226 
likely involvement of SPP in BUNV replication. In order to investigate if SPP is implicated in 227 
replication of other bunyaviruses, we infected the transduced A549V cells with SBV 228 
(Orthobunyavirus genus), RVFV (Phlebovirus genus) and Puumala virus (PUUV, Hantavirus 229 
genus), and their N proteins and virus titres were determined by WB and plaque assay. A 230 
significant inhibitory effect of SPP silencing was observed for SBV (Fig. 6D and 6E). For RVFV, 231 
Inhibition was noticeable but to lesser extent than BUNV and SBV (not statistically 232 
significant) (Fig. 6F and 6G). Significant inhibition of PUUV replication was observed for 233 
PUUV replication in SPP-knockdown cells (Fig. 6H and 6I), but PUUV growth was inhibited to 234 
a great extent in shGFP control cells than in SPP-knockdown cells, evidenced by the N 235 
protein detection in SPP-knockdown cells but not in shGFP control at 72 hrs p.i. (Fig. 6H, 236 
lane 7 at bottom panel of long exposure) and significantly lower virus titre in shGFP control 237 
(Fig, 6I). This pattern for PUUV is largely due to antiviral activity we found present in shGFP 238 
lentivirus preparation (Fig. S5A), to which PUUV is more sensitive to the inhibitory effect on 239 
virus replication than BUNV to the inhibition effect (Fig. S5B).  240 
The inhibitory effect of SPP knockdown on BUNV infection was also visualized using a 241 
recombinant virus (rBUNGc-eGFP) with eGFP fused to Gc (3). Naïve Huh7 cells and cells 242 
expressing shSPP2 were infected with rBUNGc-eGFP (MOI of 0.01), and cells were examined 243 
at 10, 24 and 48 hrs p.i. by fluorescence microscopy. Production of eGFP-tagged Gc, and 244 
hence production of progeny virus particles, was observed in naïve cells at 10 hrs p.i. and 245 
virus spread to adjacent cells was clearly evident at 24 hrs p.i. All cells were infected by 48 246 
hrs p.i. (Fig 6J, panels a to c). In SPP-knockdown cells, the eGFP-tagged Gc was not observed 247 
until 24 hrs p.i., and the spreading to neighboring cells was still limited at 48 hrs p.i. (panels 248 
d to f).  249 
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 250 
Discussion 251 
The cleavage between BUNV Gn and NSm has long been thought to occur at the amino 252 
acid motif RV/AAR, which is conserved in several orthobunyaviruses (10, 11) and fits the 253 
minimum furin cleavage site (RXXR)(28). However, as the furin-like proprotein convertases 254 
(PCs) process substrates in the lumen of the Golgi complex and endosome or at the cell 255 
surface (29), it is unlikely that the RxxR motif in the Gn CT can be accessed by these 256 
proteases. Moreover, some members of the genus Orthobunyavirus, such as Wyeomyia 257 
virus (WYOV), SBV and OROV lack the RxxR motif (Fig. S1C). In fact, we have proven that the 258 
motif and the downstream eight residues (residues 303 to 310) are still part of Gn CT. In the 259 
Bunyaviridae family, the furin-like protease is involved in the GPC processing of CCHFV 260 
(Nairovirus genus) for generating a 38-kDa NSm protein, whereas the CCHFV furin site is 261 
located at the ectodomain of pre-Gn protein (30).  262 
By using mutagenesis and MS analysis we confirmed that the NSm domain-I is SPNSm 263 
which is cleaved by SPase at residue 332T of mature NSm. The residual SPNSm, which is still 264 
linked to the upstream Gn CT (as preGn), is further processed from Gn C-terminus by the 265 
ER-resident SPP. The implication of SPP in BUNV GPC process is validated by our 266 
observations: 1) The further processing of NSm domain-I (SPNSm) upon SPase cleavage, 2) 267 
the detection of preGn by WB analysis of V5-tagged Gn protein, and 3) Inhibition of BUNV 268 
and SBV infection in SPP-knockdown cells. We also assessed the impact of SPP knockdown 269 
on two other bunyaviruses, RVFV (Phlebovirus) and PUUV (Hantavirus). SPP knockdown had 270 
no significant inhibitory effect on RVFV infection, whereas it inhibited PUUV infection. 271 
However, as PUUV replicated less efficiently in the shGFP-induced cells, we were unable to 272 
draw a clear conclusion. Some lentivirus expressing shRNAs can trigger IFN activation(31) 273 
and the effect of siRNA on innate immunity is sequence and structure related (32). It should 274 
 13 
be mentioned that the coding strategies and sizes of products encoded by M segments of 275 
the viruses in the family are very divergent and thus it is plausible that the precursor 276 
processing differs from genus to genus.  277 
Besides its role as a SP, we provide evidence that the liberated SPNSm has post-cleavage 278 
function in cell fusion. We speculate that the liberated SPNSm is likely incorporated into the 279 
virion by interacting with one of viral glycoproteins upon cleavage by SPP, which is probably 280 
required for that interaction. However, we were unable to find the peptide from the 281 
purified virus particles by MS analyses, perhaps due to the technical challenge for the 282 
reason of the small size and hydrophobicity of the domain. Another possibility is that the Gn 283 
CT is modified during the processing of SPNSm by SPP and that modification might be crucial 284 
for glycoprotein activities. Whatever the cases, it seems that the sequence specificity of 285 
SPNSm is important. Several signal peptides of viral proteins have post-cleavage functions. 286 
For instance, SPGP-C of lymphocytic choriomeningitis virus and Junín virus (Arenaviruses) 287 
precursor glycoproteins C (GP-C) is an essential structural component of mature virions and 288 
is required in both glycoprotein maturation, cell fusion and virus infectivity (33-35).  289 
Based on our findings, we propose a new model for the process and topology of 290 
orthobunyavirus glycoproteins (Fig. 7A). All three proteins, in precursor form, contain their 291 
own SPs. The N-terminal SPGn targets the nascent Gn polypeptide through the ER membrane 292 
where it is cleaved by SPase at residue 17S. The internal SPNSm mediates the translocation of 293 
the nascent NSm chain into the ER membrane and it is subsequently cleaved at residue 294 
332T by SPase from the NSm. SPNSm is further processed by SPP to free the Gn CT. NSm 295 
domain-V/SPGc translocates the nascent Gc chain to the ER membrane and is cleaved at 296 
residue 478E to separate the mature NSm and the nascent Gc chain. However, unlike SPNSm, 297 
the domain-V/SPGc is not further processed and remains as the C-terminal domain of mature 298 
NSm. The new topology model of mature Gn, NSm and Gc proteins is illuminated in Fig. 7B. 299 
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Gn and Gc proteins are type I transmembrane proteins and NSm is a two-membrane-300 
spanning protein.  301 
This study revealed a new dimension for SPP in virus replication. The new knowledge 302 
will benefit vaccine development and help identify new antiviral drugs against pathogenic 303 
virus infections caused by viruses in the family. Indeed, with the knowledge we gained we 304 
have generated recombinant BUNV and SBV viruses that lack full mature NSm as well as NSs 305 
proteins (Shi; et al., unpublished data) and these viruses would be potential candidates or 306 
tools for vaccine development.  307 
 308 
Materials and Methods 309 
The materials and methods are described in SI Materials and Methods. They include 310 
antibodies, plasmids and mutagenesis, transfection of cells, metabolic radiolabeling and 311 
immuno-precipitation, immunofluorescence staining, BUNV glycoprotein fusion assay, virus 312 
rescue by reverse genetics, virus infection, titration and purification, preparation of 313 
BUNV glycoprotein Gn, Gc and NSm proteins, mass spectrometric (MS) Analysis, SPP 314 
knockdown by lentivirus shRNA, western blotting (WB).  315 
Cells and Viruses. A549, A459V (36), A549-NPro (37), Vero E6, BHK-21, HEK 293T, Huh7 316 
and BSR-T7/5 (38) cells were maintained as described previously (4). BUNV, SBV, RVFV 317 
(strain MP12) and Puumala virus (PUUV, strain CG1820) were used as representative 318 
strains for genera of Orthobunyavirus, Phlebovirus and Hantavirus in SPP knockdown assays. 319 
rBUNGc-eGFP is a recombinant BUNV with the truncated Gc tagged by eGFP (3). 320 
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Statistical Analysis. Data were expressed as the mean and SD. The P value and statistical 321 
significance of difference was analyzed by using unpaired t test with GraphPad 6 software. 322 
*P value < 0.05, significant; **P< 0.01, very significant; ***P <0.001, extremely significant. 323 
 324 
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Figure Legend 335 
Fig. 1. Gn-NSm does not cleave at the previously predicted RVAR site. (A) Substitution and 336 
internal deletions at RVAR motif. (B) Effect of deletion and substitution mutations on GPC 337 
cleavage. (C) Internal deletions between residues 298L and 311S at Gn-NSm junction. (D) 338 
The processing of mutant GPCs. Transfected BSRT7/5 cells were radiolabeled with 339 
[35S]methionine. The viral proteins were immunoprecipitated with anti-BUN and analyzed 340 
by SDS-PAGE. The position of the viral proteins is marked.  341 
Fig. 2. NSm domain-I acts as an internal SPNSm. (A) Mutations at -3 (329I) and -1 (331G) 342 
positions of the SPase cleavage site (on pTM1-BUNM-NSmV5). (B) Effect of substitution 343 
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mutations on NSm processing. The radiolabeled viral proteins were immunoprecipitated 344 
with anti-V5 antibody. (C) Effect of mutations on the Golgi targeting of the viral 345 
glycoproteins, cell fusion and virus viability. For immunofluorescence assays, the 346 
transfected BSRT7/5 cells were stained with a mixture of anti-Gc MAb (M810, in red) and 347 
anti-GM130 (in green for the Golgi staining) antibodies and examined by confocal 348 
microscopy. Nuclei were stained in blue with DAPI. Cell fusion and virus rescue were 349 
performed as described in SI Materials and Methods. 350 
Fig. 3. Mapping the C-termini of Gn protein by mutagenesis. (A) Mutations in the Gn CT and 351 
NSm domain-I (on pTM1BUN-Gn332). ‘*’ represents the stop codon. (B) Effect of deletions 352 
on the migration shift of Gn protein. (C) Profile of the radiolabeled intracellular and virion 353 
proteins. (D) The expression of Gn332 (preGn) and Gn308V5. (E) Western blot (WB) analysis 354 
of V5-tagged Gn332 at residue 27 or 86. (F) Cell fusion assay on BSRT7/5 cells co-transfected 355 
with pTM1BUN-NSmGc (Gc) and one of the Gn mutants.  356 
Fig. 4. NSm domain-V functions as a noncleavable SPGc. (A) Deletion of Domain-V abolished 357 
the Gc processing. (B) Mutations at NSm domain-V. ‘*’ represents the stop codon. (C) Effect 358 
of deletions on the migration shift of the V5-tagged NSm protein. (D) WB analysis of V5-359 
tagged NSm and its mutants. (E) The revised topology of NSm protein. 360 
Fig. 5. Requirement of SPNSm for GPC processing, cell fusion and virus replication. (A) 361 
Schematic showing either deletion of NSm or mutations in SPNSm. (B) Effect of mutations on 362 
the GPC cleavage. (C) Cell fusion on BSRT7/5 cells transfected with BUNM mutants. (D, E 363 
and F) The protein profile (D), plaque phenotype (E) and growth curve (F) of the 364 
recombinant virus lacking NSm (rBUN∆NSm). (G) Effect of deletion mutations in SPNSm on 365 
the migration shift of Gn protein. (H) Cell fusion on BSRT7/5 cells co-transfected with 366 
pTM1BUN-NSmGc and one of the Gn mutants. 367 
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Fig 6. SPP KO affects BUNV infection. (A) SPP-knockdown in A549 cells. (B and C) WB 368 
analysis (B) and Growth kinetics (C) of BUNV infection in shRNA expressing A549V cells. (D 369 
and E) Effects of SPP-knockdown on SBV infection. (F and G) Effects of SPP knockdown on 370 
RVFV infection. (H and I) Effects of SPP-knockdown on Puumala virus (PUUV) infection. The 371 
transduced A459V cells were infected with virus (MOI of 0.01). At each time point the 372 
supernatants were harvested for virus titration and cell lysates were collected for WB. The 373 
relevant proteins were probed with antibodies against SPP, tubulin (T) or viral N proteins. (J) 374 
Effect of SPP-knockdown on BUNV spreading. Transduced Huh7 cells were infected with 375 
rBUNGc-eGFP (MOI of 0.01) and incubated until time points (10, 24 and 48 hrs p.i.) as 376 
indicated. Cells were stained with anti-GM130 and examined by confocal microscopy. EGFP-377 
tagged Gc and virus particles were shown in green, GM130 were stained in red and the 378 
nuclei were stained in blue with DAPI.  379 
Fig. 7. The model of BUNV GPC (Gn-NSm-Gc) cleavage. (A) Schematic showing BUNV GPC 380 
processing. (B) Topology of Gn, Gc and NSm proteins. See discussion for details. 381 
 382  383 
  384 
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Supporting Information 385 
SI Materials and Methods 386 
Antibodies. MAb810, a monoclonal antibody against BUNV Gc, anti-BUN and anti-NSm, 387 
the rabbit antisera against BUNV particles and NSm peptide TDQKYTLDEIADVLQA (residues 388 
338 to 353 of BUNV GPC), have been described previously (26). Rabbit anti-BUN N, anti-SBV 389 
N and anti-RVFV N antisera were raised against nucleoproteins of BUNV, SBV and RVFV, 390 
respectively(39-41). A rabbit antiserum against GM130, a cis-Golgi matrix protein was 391 
provided by Dr M. Lowe (University of Manchester, UK). Other antibodies were purchased 392 
commercially: rabbit polyclonal antibody against SPP (anti-SPP) (Abcam); mouse monoclonal 393 
antibody against the V5 epitope (anti-V5) (Serotec); goat anti-rabbit antibody conjugated 394 
with fluorescein isothiocyanate (FITC) (Sigma), and goat anti-mouse antibody conjugated 395 
with Cy5 (Chemicon International Inc).  396 
Production of Anti-PUU N. The 6His-tagged Puumala virus (PUUV) N protein was 397 
expressed in BL21-CodonPlus (DE3)-RP E. coli (Agilent Technologies) under IPTG induction at 398 
18-20 °C for 20 hrs, purified with Ni–NTA resin and its identity confirmed by mass 399 
spectrometry. The purified PUU N was used for generating rabbit antisera against PUUV N 400 
protein (Eurogentec). 401 
Plasmids and Mutagenesis. Plasmids that generate full-length BUNV antigenome RNA 402 
transcripts, pT7riboBUNL(+), TVT7R-BUNM(+), and pT7riboBUNS(+), or express the full 403 
length GPC, pTM1-BUNM, have been described previously (8, 42); pT7riboBUNM-NSmV5(+) 404 
and pTM1BUNM-NSmV5 contain the V5 epitope (GKPIPNPLLGLDST) inserted between 405 
residues 403 and 420 of the NSm coding region (Fig. S3B). The substitution and internal 406 
deletion mutations in BUNV GPC (in the backbone of either pTM1-BUNM for high 407 
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expression or pT7riboBUNM for virus rescue) were generated by PCR-directed mutagenesis 408 
on the appropriate parental templates.  409 
A series of individual Gn expression plasmids (pTM1BUNGn298 to Gn332) were derived 410 
from pTM1BUNM (Fig. 3A) and Gn-NSm expression plasmids (pTM1BUNGn-NSmV5-454 to 411 
476) were derived from pTM1BUNM-NSmV5 (Fig. 4A), in which the V5 epitope is inserted in 412 
the NSm cytoplasmic domain (IV) between residues 403 and 420 (Fig. S4B). The V5 tagged 413 
NSm was also introduced into TVT7RBUNM[+] for generating recombinant virus containing 414 
V5-tagged NSm. Two mutated Gn-NSm constructs (pTmBUNGnNSmV5-SPGc/SPHGn and 415 
pTmBUNGnNSmV5-SPGc/eGFP1-20) were created by replacement of the domain-V with either 416 
signal peptide of Hantaan virus Gn protein (residues 1 to 19) or N-terminal 20 residues of 417 
eGFP (Fig. 4A). Three mutated GPC constructs (pTM1BUNM∆446-476, ∆457-476 and ∆467-418 
476) contain internal deletions in the coding region of NSm domain IV and V).  pTM1BUN-419 
NSmGc expresses NSm and Gc proteins (residues 309 to 1433). pTmBUNM∆NSm_V and 420 
pTmBUNM∆NSm_I contain internal deletions in NSm coding region, in which ∆NSm_V has 421 
deletion of NSm domains I to IV (residues 311 to 456) except domain-V (SPGc) and 422 
pTmBUNM∆NSm_I has deletion of NSm domains II to V (residues 332 to 477) except 423 
domain-I (SPNSm) as SP for Gc. pTMBUNM-SPNSm/HTNtm has 17 residues of SPNSm (residues 424 
311 to 327) swapped with those of HTNV Gn TMD (TFCFGWVLIPAITFIIL, residues 490 to 506) 425 
(Fig. 5A). pTmBUNM-SPmNSm contains four point mutations in the coding region of NSm 426 
domain-I (Fig. 2A). All the constructs were confirmed by DNA sequencing. 427 
Transfection of Cells. BSRT7/5 cells were grown either in 35-mm dishes for 428 
immunoprecipitation experiments or in 12-well plate for cell fusion assay, or on 13-mm 429 
glass coverslips for immunofluorescence assays. Cells were transfected with the mixtures of 430 
plasmid DNA and transfection reagent (Lipofectamine® 2000 Transfection Reagent, 431 
Invitrogen) and incubated at 37°C for 24 hrs. 432 
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Metabolic Radiolabeling and Immunoprecipitation. At 24 hrs post transfection or 433 
post infection (p.i.), cells were labeled with [35S]methionine (PerkinElmer) for 3 hrs. For 434 
labelling of virus particles, the infected BHK21 cells grown in 175-cm2 flask were labelled 435 
with [35S]methionine for 6 hrs p.i. and virus particles were purified by ultracentrifugation 436 
(4). Cells were then lysed on ice in 300 µl of non-denaturing RIPA buffer (50 mM Tris-HCl 437 
[pH7.4], 1% Triton X-100, 300 mM NaCl, 5 mM EDTA) containing a cocktail of cOmplete 438 
protease inhibitors (Roche). BUNV proteins were immunoprecipitated with anti-BUN, anti-439 
NSm or anti-V5 antibodies conjugated to Dynabeads Protein A (Novex, Life Technologies). 440 
The beads bound to immune complexes were washed with RIPA buffer containing 0.1% 441 
Triton X-100 and with cold PBS, and bound viral proteins were analyzed by SDS-PAGE under 442 
reducing conditions.  443 
Immunofluorescence Staining. The transfected or infected cells were fixed with 4% 444 
formaldehyde-2% Sucrose-PBS and permeabilized with 0.2 % Triton X-100 in PBS before 445 
staining with specific primary antibodies and secondary antibody conjugates. Cells were 446 
examined using a Zeiss LSM confocal microscope. 447 
BUNV Glycoprotein Fusion Assay. BSR-T7/5 cells, grown on 12-well plates, were transfected 448 
with 1 µg of either pTM1-BUNM or one of the mutant M expression plasmids. At 24 hrs post 449 
transfection, cells were treated with low pH medium (pH 5.3) for 15 min and then the 450 
medium was replaced by GMEM supplemented with 10% foetal calf serum (FCS). After 451 
incubation for 4 hrs at 37 °C the extent of cell fusion was observed following Giemsa 452 
staining. Cells that contain more than 3 nuclei are considered as syncytia and the nuclei in 453 
30 syncytia in total were counted. The fusion is represented as average nuclei per syncytium 454 
(n = 30).  455 
Virus Rescue by Reverse Genetics.  Rescue experiments were performed essentially 456 
as described previously with minor modifications (42). Sub-confluent monolayers of BSR-457 
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T7/5 cells grown in T25 were transfected with a mixture of plasmids comprising 1.0 µg each 458 
of pT7riboBUNL(+), pT7riboBUNS(+) and TVT7RBUNM(+) or one of the M cDNA mutants, 459 
and 7.5 µl Lipofectamine 2000 (Life Technologies) in 0.7 ml Opti-MEM media (Life 460 
Technologies). At 4 hrs post transfection, 4 ml growth medium was added and incubation 461 
continued at 33°C until CPE was evident. 462 
Virus Infection, Titration and Purification. Cells seeded in dishes or flasks were 463 
infected at an MOI of 0.01 or 1.0 PFU/cell. The inoculum was removed after 1hrs, and cells 464 
were washed with PBS to remove the unattached viruses. Supernatants were harvested at 465 
the indicated time points. BUNV and SBV were titrated by plaque assay on BSRT7/5 cells 466 
and RVFV on BHK21 cells. The PUUV was titrated on Vero E6 cells by using the Avicel 467 
immunofocus assay. Briefly, the virus infected cells were covered with 0.6% Avicel (FMC 468 
BioPolymer) overlay medium and incubated for 7 days, fixed with 4% formaldehyde-PBS and 469 
permeabilized with 0.5% Triton-100, 20mM glycine-PBS.  Cell monolayer was blocked with 4% 470 
skimmed milk, reacted with anti-PUUN and probed with peroxidase-conjugated anti-rabbit 471 
IgG. The foci were developed after incubation with True Blue peroxidase substrate (KPL). 472 
The purification of BUNV particles was described previously (4). 473 
Preparation of BUNV Glycoprotein Gn, Gc and NSm Proteins.  BUNV NSm 474 
protein was purified from lysate of the rBUNV-NSmV5 infected cells using anti-V5 Affinity 475 
gel (biotool.com). Briefly, BHK-21 cells were infected with rBUNV-NSmV5 and cells were 476 
harvested 48 hrs p.i. when cells showed obvious cytopathic effect (CPE). The cell pellet was 477 
lysed with non-denaturing RIPA buffer and mixed with anti-V5 Affinity bead. The V5-tagged 478 
NSm protein (NSmV5) was separated by 15% Tris-glycine SDS-PAGE (Fig. S3C). For 479 
preparation of BUNV Gn and Gc proteins, the purified BUNV particles were separated by 480 
12.5% Tris-glycine SDS-PAGE and stained with Coomassie Brilliant Blue G-250 solution (Fig. 481 
S3E). Gn and Gc bands were excised for mass spectrometric analysis. 482 
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Mass Spectrometric (MS) Analysis. Protein bands were cut into 1mm cubes, which 483 
were then subjected to in-gel digestion with either glutamyl endopeptidase (GluC) (NEB), 484 
AspN (NEB) or trypsin (Promega) by a ProGest Investigator in-gel digestion robot (Genomic 485 
Solutions, Ann Arbor, MI) using standard protocols (43). Briefly the gel cubes were de-486 
stained by washing with acetonitrile and subjected to reduction and alkylation before 487 
digestion with endoproteinase at 37°C. The peptides were then extracted with 10% formic 488 
acid and concentrated down to 20 µL using a SpeedVac (ThermoSavant). In some GluC 489 
digestions of Gn protein PMSF (1mM) was added to prevent any trypsin-like proteolytic 490 
cleavage. The peptides were then separated on an Acclaim PepMap 100 C18 trap and an 491 
Acclaim PepMap RSLC C18 column (Thermo Fisher Scientific), using a nanoLC Ultra 2D plus 492 
loading pump and nanoLC as-2 autosampler (Eksigent). The peptides were eluted with a 493 
gradient of increasing acetonitrile, containing 0.1 % formic acid (5-40% acetonitrile in 5 min, 494 
40-95% in a further 1 min, followed by 95% acetonitrile to clean the column, before 495 
reequilibration to 5% acetonitrile). The eluate was sprayed into a TripleTOF 5600+ 496 
electrospray tandem mass spectrometer (Sciex) and analyzed in Information Dependent 497 
Acquisition (IDA) mode, performing cycles of 250 msec of MS followed by 100 msec MSMS 498 
analyses on the 15 most intense peaks seen by MS. The MS/MS data file generated via the 499 
‘Create mgf file’ script in PeakView (Sciex) was analyzed using the Mascot algorithm (Matrix 500 
Science), against an internal database to which the amino acid sequence of the BUNV 501 
glycoprotein precursor (Accession number P04505), had been added, with GluC, AspN, or 502 
trypsin as the cleavage enzyme and carbamidomethyl as a fixed modification of cysteines 503 
and methionine oxidation and deamidation of glutamines and asparagines as a variable 504 
modifications, followed by an ‘error tolerant’ search, to look for peptides where only one 505 
end conforms to the enzyme specificity criteria, in order to delineate the C-terminal peptide 506 
sequence.  507 
 23 
SPP Gene (HM13) Knockdown by Lentivirus shRNA. Short hairpin RNA (shRNA) 508 
cDNAs specific for human SPP (nt 777 – 795 for shSPP1 and 1034 – 1052 for shSPP2, 509 
Accession No: AJ420895) and eGFP (nt 441 – 463, Accession No: U57607) as control were 510 
cloned into pLKO.1 puro (Addgene). Lentivirus stocks were prepared in HEK 293T cells by 511 
transfection of constructs: pLKO, pMD-G (pVSVG), a plasmid expressing the vesicular 512 
stomatitis virus glycoprotein (VSV-G)(44), and pCMV∆R8.91 (pCMV-R), a plasmid expressing 513 
the gag/pol rev genes of HIV-1(45), with Lipofectamine 2000 (Invitrogen). shRNA expression 514 
in A549 or A549V cells was achieved by transducing cells with shRNA-expressing lentiviruses 515 
for 48 hrs in the presence of 8 µg/ml polybrene (Santa Cruz Biotechnology).  516 
Western Blotting (WB). Lysates of plasmid-transfected or virus-infected cells were prepared 517 
by the addition of 100 µl NuPAGE LDS sample buffer (Life Technologies) containing 1µl 518 
Benzonase nuclease (Merck Millipore). Proteins were separated on 4 - 12% Bis-Tris protein 519 
gel (Life technologies) and transferred to a Nitrocellulose Blotting Membrane (GE 520 
Healthcare). The membrane was probed with appropriate antibodies and signals detected 521 
by chemiluminescence. 522 
 523 
SI Figure Legends 524 
Fig. S1. Schematic of BUNV GPC and mutations at RVAR motif and Amino acid sequence 525 
alignment at the BUNV Gn-NSm junction. (A) BUNV GPC with positions of amino acid 526 
residues marking the predicted boundaries (Gn, NSm and Gc) indicated. The amino acid 527 
sequence and the secondary structure prediction at the Gn-NSm junction (residues 295 to 528 
350) are shown below. RVAR motif (residue 299 to 302) is in bold. The epitope to anti-NSm 529 
is underlined. The secondary structure is projected using HMMTOP server 530 
(http://www.enzim.hu/hmmtop/) with ‘H’ indicating hydrophobic transmembrane helix, ‘i’ 531 
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residue on inside and ‘O’ residues outside of transmembrane domains (TM/TMD). The NSm 532 
domains (I to V) (8) are shown under the NSm coding region. Signal peptide (SP) and TM are 533 
shown as grey and black boxes respectively. (B) Alignment between BUNV and SSHV GPCs. 534 
The previously predicted last C-terminal residues are arginine (R) at residue 302 for BUNV 535 
and residue 299 for SSHV (in bold). (C) Amino acid sequence alignment of 13 536 
orthobunyavirus GPCs (aligned to residues 294 to 335 of BUNV GPC). The alignment was 537 
created by using EMBL-EBI Clustal Omega program (www.ebi.ac.uk/Tools/msa/clustalo/). 538 
The conserved arginine residues at residue 302 (for BUNV) are in bold. The Accession 539 
numbers of orthobunyavirus glycoprotein precursors used in alignment: Bunyamwera virus 540 
(BUNV, P04505), Maguari virus (MAGV, AAQ23639), Kairi virus (KRIV, ACV89517), Wyeomyia 541 
virus (WYOV, AGA54137), Cachoeira Porteira virus (CPV, AEZ35284), Snowshoe hare virus 542 
(SSHV, ABX47014), La Crosse virus (LACV, AAB62804), California encephalitis virus (CEV, 543 
AAD53039), Inkoo virus (INKV, AAB93841), Schmallenberg virus (SBV, AGC93514), Douglas 544 
virus (DOUV,  HE795091), Simbu virus (SIMV, YP_006590085), Oropouche virus (OROV, 545 
AGH07923) and Oya virus (OYAV, AGS56983).  546 
Fig. S2. Effect of Furin inhibitor on BUNV infection. BUNV-infected Vero E6 cells (MOI of 547 
0.01 pfu/cell) were incubated for 30 hours in the presence of different concentrations (0, 548 
12.5, 25, 50 and 100 µM) of furin inhibitor I (dec-RVKR-cmk, Calbiochem) and viral 549 
replication was evaluated by immunoprecipitation and virus titration. (A) Effect of the furin 550 
inhibitor I on GPC cleavage. Lane 2 is mock infected. (B) Yield of virus in the presence of 551 
Furin inhibitor I, the concentrations of which are similar to those that inhibit furin-mediated 552 
cleavage of the respiratory syncytial virus (RSV) fusion protein (46). 553 
Fig. S3. Mass spectrometric (MS) analysis of BUNV NSm. (A) SP Prediction of NSm domain-I 554 
using SignalP 4.1 (www.cbs.dtu.dk/services/SignalP/) (22) with cleavage between residues 555 
331G and 332T. (B) The V5-tagged NSm (NSmV5). V5 epitope is inserted in the NSm 556 
 25 
cytoplasmic domain (IV) between residues 403 and 420. (C) Purification of NSm from cells 557 
infected with recombinant rBUNV-NSmV5. The V5-tagged NSm gel band was excised, 558 
subject to in-gel digestion and mass spectrometric analysis. (D) MS/MS fragment pattern for 559 
the NSm N-terminal residues. 560 
Fig. S4. Mass spectrometric (MS) analysis of BUNV Gn and Gc. (A) Coomassie Blue stained 561 
viral proteins of purified virus particles. (B to D) MS/MS fragment patterns for the terminal 562 
residues at Gn N-terminus (B) Gn C-terminal region (C) and Gc N- terminus (D). 563 
Fig. S5. shGFP lentivirus contains antivirus activity. (A) Biological IFN assay. A549/Npro cells 564 
were treated with series-diluted IFNα (pbI assay science), lentivirus or cell medium for 24 565 
hrs and then challenged with EMCV (at moi of 0.1) for 48 hrs or until obvious CPE occurs. 566 
Cells were fixed and stained 4% formaldehyde-0.1% crystal violet solution. (B) Comparison 567 
of BUNV and PUUV infections responsive to shGFP lentivirus. The induced and naive cells 568 
were treated with different dilutions of shGFP lentivirus and infected with either BUNV or 569 
PUUV at moi of 0.1. The result was shown as fold inhibition of virus titres between the 570 
induced and non-induced cells. 571 
 572 
573 
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SI Table. Summary of N- and C-terminal amino acids of Gn, NSm and Gc 574 
proteins identified by mass spectrometry. 575 
 Enzyme Amino acid sequence and position 
Gn  
N-terminal 
GluC 
+PMSF 
17SPVITRCFHGGQLIAE 
 
Gn 
C-terminal 
GluC 
+PMSF 
 
SGLCQGFK 296 
SGLCQGFKS297  
SGLCQGFKSLR299  
SGLCQGFKSLRVAR302 
SGLCQGFKSLRVARR303  
 AspN DRMRMHRESGL291 
 Tryp 
 
ESGLCQGFK296 
ESGLCQGFKSLR299 
NSm 
N-terminal 
GluC 
 
332TLTNYPTDQK 
NSm 
C-terminal 
GluC 
 
CGFCTCGLLEDPEGVVVHK441 
 
Gc  
N-terminal 
Tryp 478EEDCWK 
Gc  
C-terminal 
Tryp LYLQEIK1431 
Abbreviation of Endoproteinases: GluC, Glutamyl endopeptidase; AspN, 576 
Peptidyl-Asp metalloendopeptidase,  Tryp, trypsin. 577  578  579 
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